论文部分内容阅读
目的评价莫西沙星和头孢哌酮舒巴坦治疗早发性卒中相关性肺炎(early-onset stroke associated pneumonia,EOP)临床疗效及细菌学疗效。方法 101例早发性卒中相关性肺炎患者随机分为莫西沙星治疗组和头孢哌酮舒巴坦治疗组,观察两组临床疗效、细菌清除率及多重耐药菌检出情况。结果莫西沙星治疗组和头孢哌酮舒巴坦治疗组临床有效率、细菌清除率分别为76.47%vs 80.00%和80.39%vs 84.21%;两组临床有效率和细菌清除率差异无统计学意义(χ2=0.182,P=0.075vsχ2=1.235,P=1.068);莫西沙星治疗组共检出鲍曼不动杆菌24株,头孢哌酮舒巴坦治疗组36株,两者比较差异有统计学意义(χ2=7.136,P=0.036)。结论莫西沙星治疗EOP在临床疗效和清除率方面与头孢哌酮舒巴坦相当,且其耐药鲍曼不动杆菌产生和耐药性低于后者,可以作为治疗EOP的安全、有效的首选药物之一。
Objective To evaluate the clinical efficacy and bacteriological efficacy of moxifloxacin and cefoperazone sulbactam in the treatment of early-onset stroke associated pneumonia (EOP). Methods A total of 101 patients with early-stroke stroke-associated pneumonia were randomly divided into two groups: moxifloxacin group and cefoperazone-sulbactam group. Clinical efficacy, bacterial clearance rates and detection of multi-drug resistant bacteria in both groups were observed. Results The clinical effective rate and bacterial clearance rate in the moxifloxacin group and the cefoperazone sulbactam group were 76.47% vs 80.00% and 80.39% vs 84.21%, respectively. There was no significant difference in clinical efficacy and bacterial clearance between the two groups (χ2 = 0.182, P = 0.075vsχ2 = 1.235, P = 1.068). There were 24 strains of Acinetobacter baumannii and 36 cases of cefoperazone sulbactam in the moxifloxacin group, with statistical difference Significance (χ2 = 7.136, P = 0.036). Conclusion Moxifloxacin treatment of EOP in clinical efficacy and clearance rate with cefoperazone sulbactam quite, and the drug-resistant Acinetobacter baumannii lower than the latter and can be used as a safe and effective treatment of EOP One of the preferred drugs.